Connect with us


DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Fennec Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm


Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Middle District of North Carolina on behalf of investors that purchased Fennec Pharmaceuticals, Inc. (NASDAQ: FENC) securities between February 11, 2020 and August 10, 2020 (the Class Period). Investors have until November 2, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

Fennec is a biopharmaceutical company that purportedly focuses on the development of PEDMARK, a sodium thiosulfate anhydrous injection, for the prevention of platinum-induced ototoxicity in pediatric cancer patients.

On August 11, 2020, Fennec disclosed that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Companys New Drug Application for PEDMARK. According to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of [Fennecs] drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.

On this news, the Companys share price fell $3.51, or 34%, to close at $6.66 per share on August 11, 2020.

The complaint, filed on September 3, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the manufacturing facilities for PEDMARK, the Companys sole product candidate, did not comply with current good manufacturing practices; (2) that, as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased Fennec securities during the Class Period and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato, Marion Passmore, or Brandon Walker by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit Attorney advertising. Prior results do not guarantee similar outcomes.

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

[email protected]


QK Alert: Johnson Fistel Launches Investigation into Q&K International – Stock Price has Plummeted Since IPO; Investors Suffering Losses Encouraged to Contact the Firm


SAN DIEGO, Dec. 1, 2020 /PRNewswire/ — Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Q&K International Group Limited (“Q&K” or the “Company”) (NASDAQ: QK) for violations of federal securities laws.

On or about November 5, 2019, Q&K sold about 2.7 million shares of stock in its initial public stock offering (the “IPO”) at $17.00 a share, raising nearly $50 million in new capital. On November 30, 2020, the stock closed at $3.65.

Specifically, Johnson Fistel's investigation seeks to determine whether the Company's filings with the U.S. Securities and Exchange Commission in connection with its November 2019 IPO and subsequent investor communications contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the Company's business, and operations.

If you have information that could assist in this investigation, or if you are a Q&K shareholder and are interested in learning more about the investigation, please contact Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.

Additionally, you can [Click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.

Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]

[Click here to join this action]


Cision View original content:—stock-price-has-plummeted-since-ipo-investors-suffering-losses-encouraged-to-contact-the-firm-301182445.html

SOURCE Johnson Fistel, LLP

Continue Reading


Gerdau S.A. Announces Results Of Early Tender Period Of The Cash Tender Offer For Certain Of The Outstanding 5.750% Bonds Due 2021, 4.750% Bonds Due 2023, 5.893% Bonds Due 2024 And 4.875% Bonds Due 2027 And Upsizing Of The Cash Tender Offer


SÃO PAULO, Dec. 1, 2020 /PRNewswire/ — Gerdau S.A. (Bovespa: GGBR, NYSE: GGB, Latibex: XGGB) (“Gerdau” or the “Company”) hereby announces the results of the early tender period under the previously announced offer by the Company to purchase for cash (the “Tender Offer”) up to a maximum tender consideration of U.S. $230,000,000 (including the Early Tender Payment, if applicable) of certain of the outstanding 5.750% Bonds due 2021 (the “2021 Bonds”) issued by Gerdau Trade Inc. (“GTI”), 4.750% Bonds due 2023 (the “2023 Bonds”) issued by  GTI, 5.893% Bonds due 2024 (the “2024 Bonds”) issued jointly by Gerdau Holdings, Inc. (“GHI”) and GTL Trade Finance Inc., (“GTL”) and the 4.875% Bonds due 2027 (the “2027 Bonds”, and together with the 2021 Bonds, the 2023 Bonds and the 2024 Bonds, the “Bonds” and each, a “series” of Bonds) issued by GTI (GTI, GHI and GTL, collectively, the “Offerors”). The Tender Offer is being made pursuant to the offer to purchase dated November 16, 2020 (the “Offer to Purchase”). Capitalized terms used but not defined in this press release shall have the meanings assigned to them in the Offer to Purchase.

The Tender Offer was oversubscribed as of 5:00 P.M., New York City time, on the Early Tender Date.  The Offerors have agreed, however, to increase the tender offer to accept for purchase an aggregate of U.S. $300,007,000 principal amount of the Bonds, so that the “Aggregate Maximum Tender Consideration” (as defined in the Offer to Purchase) has been increased to U.S.$ 335,887,519.22.   Accordingly, the Company will not accept for purchase any additional Bonds tendered after the Early Tender Date.  As the Tender Offer was oversubscribed, Bonds tendered at or prior to the Early Tender Date were accepted in accordance with the Acceptance Priority Level (as defined in the Offer to Purchase) and proration, in the amounts set forth in the table below. No 2023 Bonds or 2027 Bonds were accepted for purchase.

The principal amount of each series of Bonds that were validly tendered and not validly withdrawn in the Tender Offer as of the Early Tender Date and the principal amount of each series of Bonds that have been accepted for purchase by the Company are set forth in the table below.


Description of Bonds



Acceptance Priority


Principal Amount Tendered

Principal Amount Accepted

5.750% Bonds due 2021

G3925DAA8 / USG3925DAA84
37373WAA8 / US37373WAA80



U.S. $29,056,000

U.S. $29,056,000

5.893% Bonds due 2024

G24422AA8 / USG24422AA83
36249SAA1 / US36249SAA15



U.S. $349,433,000

U.S. $270,951,000

4.750% Bonds due 2023

G3925DAB6 / USG3925DAB67

37373WAB6 / US37373WAB63



U.S. $74,993,000

U.S. $0

4.875% Bonds due 2027

G3925DAD2 / USG3925DAD24

37373WAD2 / US37373WAD20



U.S. $96,059,000

U.S. $0

The Tender Offer is subject to, and conditioned upon, the satisfaction or waiver of certain conditions as set forth in the Offer to Purchase. 

Gerdau will deliver cash with respect to such validly tendered and accepted Bonds on December 2, 2020.

On the Early Settlement Date, eligible holders of Bonds that were validly tendered prior to the Early Tender Date, and whose Bonds were accepted for purchase, will be entitled to receive total consideration of (i) U.S. $1,008.62 for each U.S. $1,000 principal amount of the 2021 Bonds and (ii) U.S. $1,131.50 for each U.S. $1,000 principal amount of the 2024 Bonds, which includes, in each case, the Early Tender Payment of U.S. $50.00  per U.S. $1,000 principal amount of the Bonds. In addition, such eligible holders will be entitled to receive a cash payment equal to the accrued and unpaid interest on such Bonds up to, but not including, the Early Settlement Date.

The Tender Offer will expire at 11:59 p.m. New York City time, on December 14, 2020, unless extended or earlier terminated. The withdrawal deadline for the Tender Offer was 5:00 p.m., New York City time, on November 30, 2020 and so has passed.  Accordingly, Bonds tendered (in the past or future) in the Tender Offer may no longer be withdrawn, except if required by applicable law.

The Information and Tender Agent for the Tender Offer is D.F. King & Co. To contact the Information and Tender Agent, banks and brokers may call (866) 207-3636 or email [email protected].

The Dealer Managers for the Tender Offer are BofA Securities, Inc. and Goldman Sachs & Co. LLC (the “Dealer Managers”). Any questions or requests for assistance may be directed to BofA Securities, Inc. at Collect: +1 (646) 855-8988 or U.S. Toll-Free: +1 (888) 292-0070, or Goldman Sachs & Co. LLC at U.S.: +1 (212) 357-1452 or by email at [email protected].  In addition, Holders may contact their broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Tender Offer.

Documents in connection with the Tender Offer are available at the offices of the Information Agent, D.F. King & Co., Inc., 48 Wall Street, 22nd Floor, New York, New York 10005, Attn: Andrew Beck.  

This notice does not constitute or form part of any offer or invitation to purchase, or any solicitation of any offer to sell, the Bonds or any other securities in the United States or any other country, nor shall it or any part of it, or the fact of its release, form the basis of, or be relied on or in connection with, any contract therefor. The Tender Offer is made only by and pursuant to the terms of the Offer to Purchase and the information in this notice is qualified by reference to the Offer to Purchase. None of the Dealer Managers or the Information and Tender Agent make any recommendations as to whether Holders should tender their Bonds pursuant to the Tender Offer.

This notice to the market does not represent an offer to sell securities or a solicitation to buy securities in the United States or in any other country.

This notice to the market is released for disclosure purposes only, in accordance with applicable legislation. It does not constitute marketing material and should not be interpreted as advertising an offer to sell or soliciting any offer to buy securities issued by any of the Offerors. This notice to the market is not for distribution in or into or to any person located or resident in the United States, its territories and possessions, any state of the United States or the District of Columbia or in any jurisdiction where it is unlawful to release, publish or distribute this announcement, other than any exemption thereunder.

Forward-Looking Statements

This notice includes and references “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may relate to, among other things, the Offerors' business strategy, goals and expectations concerning its market position, future operations, margins and profitability.

Although the Offerors believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect.

The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and trends to differ materially from those made, projected, or implied in or by the forward-looking statements depending on a variety of uncertainties or other factors.

The Offerors undertake no obligation to update any of their forward-looking statements.


Cision View original content:–4-750-bonds-due-2023–5-893-bonds-due-2024-and-4-875-bonds-due-2027-and-upsizing-of-the-cash-te-301182287.html

SOURCE Gerdau S.A.

Continue Reading


Sky Medical's CCO to speak at GIANT Health Event on NHS Med-Tech innovation adoption


·  Sky Medical's CCO, Andrew Thelwell, to speak at GIANT Health Event 2nd December 2020

·  GIANT Health is the biggest healthcare technology event in Europe

·  Andrew will discuss the challenges in bringing Med-Tech innovation into NHS clinical practice

HIGH WYCOMBE, England, Dec. 1, 2020 /PRNewswire/ — Sky Medical Technology's Chief Commercial Officer, Andrew Thelwell, will be speaking at Europe's biggest healthcare technology event, the Global Innovation and New Technology (GIANT) Health Event, taking place online on 2nd December 2020.

Sky Medical Technology CCO  Andrew Thelwell

Andrew Thelwell will be joining a panel of experts on the BOB.Health conference track, 'NHS Spread and Scale: from one to many', to discuss how innovative medical technology can impact care provided by the NHS.

GIANT Health Event brings together thousands of health technology innovators, entrepreneurs, physicians, corporate leaders and investors to discuss the key health and care issues and showcase the latest health technologies.

Sky's innovative geko™ device is in routine use across six NHS trusts, with a further 28 NHS hospitals working to embed the device within their post-stroke VTE prevention care pathway. The small wearable device, the size of a wristwatch, sticks to the leg to increase blood flow via painless electrical pulses, at a rate equal to 60 per cent of walking without a patient having to move.

Andrew Thelwell, Chief Commercial Officer of Sky Medical Technology, says: “Deployment of Med-Tech innovation into the NHS requires an understanding of the critical enablers – the generation of robust clinical and health economic data – coupled with a deep appreciation of the real, practical barriers that can prevent transformational change. Asking the NHS to adopt a technology, even for a recognized unmet need, is asking them to adapt, and I look forward to discussing this challenge in particular with the BOB.Health panel on December 2nd. I look forward to sharing insights into the hard work and personal commitment of the Royal Stoke Hospital clinical team in bringing the geko™ device across the line for post-stroke VTE prevention.”

BOB.Health is a new, free-to-NHS shared learning platform designed to help spread good practice and learnings across the NHS through 'impact stories' that describe the processes other clinicians may wish to follow to replicate change to clinical practice.

Neil Crump, Co-founder and Chief Partnership Officer of BOB.Health, says: “We are chuffed to welcome Andrew as a speaker on our track at GIANT to discuss the important topic of medical technology adoption in the NHS. We're thrilled to also welcome BOB's first sponsored impact story detailing how the geko™ device is being implemented in practice at the Royal Stoke University Hospital, all told from the perspective of the NHS staff member who made it happen. We look forward to further collaborating with Sky Medical Technology to tell stories of further adoption.”

For more information about GIANT Health Event 2020 and to buy tickets, visit:

About Sky Medical Technology:

Sky Medical Technology Ltd, the parent of Firstkind Ltd, is a UK-based medical devices company.  Through its innovative mechanism of neuromuscular electrostimulation, Sky has developed a non-invasive, ground-breaking technology platform, OnPulse™, embedded in its industry-leading brand, the geko™ device. Sky's products are tailored to different medical application areas, selling through strategic partnerships or distributors in each clinical area. Clinical areas of focus include the prevention of life-threatening blood clots, complications related to swelling after orthopaedic surgery and vascular conditions related to wound healing. The goal in each pathway is to partner with healthcare professionals to improve clinical outcomes and patient care whilst saving health system resources.

Photo –
Photo –
Logo –


The geko™ device on the leg


Sky Medical Technology Logo

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News3 mins ago

Tuniu Announces Unaudited Third Quarter 2020 Financial Results

NANJING, China, Dec. 1, 2020 /PRNewswire/ — Tuniu Corporation (NASDAQ: TOUR) (“Tuniu” or the “Company”), a leading online leisure travel company...

gbafNews28 gbafNews28
News3 mins ago foresees that 85 per cent of the contracts will be digital after the coronavirus pandemic

GENEVA and, MADRID, Dec. 1, 2020 /PRNewswire/ —, the Spanish technology services company (OTCQX:LLEIF) (BME:LLN) (EPA:ALLLN), foresees a new boom in digital...

gbafNews28 gbafNews28
News3 mins ago

Thrasio Expands German M&A Effort, Commits $225 million to Acquire German Ecommerce Businesses

BOSTON and NEW YORK, Dec. 1, 2020 /PRNewswire-PRWeb/ — Today Thrasio announced a significant expansion of its German operations, including the...

gbafNews28 gbafNews28
News3 mins ago

BMO Financial Group Reports Fourth Quarter and Fiscal 2020 Results

Financial Results Highlights Fourth Quarter 2020 Compared With Fourth Quarter 2019: Net income4 of $1,584 million, up 33%; adjusted net income1...

gbafNews28 gbafNews28
News3 mins ago

Gerdau S.A. Announces Results Of Early Tender Period Of The Cash Tender Offer For Certain Of The Outstanding 5.750% Bonds Due 2021, 4.750% Bonds Due 2023, 5.893% Bonds Due 2024 And 4.875% Bonds Due 2027 And Upsizing Of The Cash Tender Offer

SÃO PAULO, Dec. 1, 2020 /PRNewswire/ — Gerdau S.A. (Bovespa: GGBR, NYSE: GGB, Latibex: XGGB) (“Gerdau” or the “Company”) hereby announces...

gbafNews28 gbafNews28
News3 mins ago

China Zenix Auto International Limited Reports 2020 Third Quarter Financial Results

ZHANGZHOU, China, Dec. 1, 2020 /PRNewswire/ — China Zenix Auto International Limited (OTC: ZXAIY) (“Zenix Auto” or “the Company”), one of the...

gbafNews28 gbafNews28
News3 mins ago

Queen City Angels Closes Investment in Emerging RegTech Company, Joot

CINCINNATI, Dec. 1, 2020 /PRNewswire-PRWeb/ — Queen City Angels (QCA) today announced an investment in Joot, a regulation technology (RegTech) company...

gbafNews28 gbafNews28
News3 mins ago

BMO Financial Group Declares Dividends

TORONTO, Dec. 1, 2020 /PRNewswire/ — Bank of Montreal (TSX: BMO) (NYSE: BMO) today announced that its Board of Directors declared...

gbafNews28 gbafNews28
News3 mins ago

Life Settlement Pioneer Launches for Financial Advisors

ATLANTA, Dec. 1, 2020 /PRNewswire/ — Life insurance settlement industry pioneer Wm. Scott Page recently announced the launch of, a...

gbafNews28 gbafNews28
News3 mins ago

TORA's OEMS Integrates with Liquidnet's IA Trader to Offer Real Time Actionable Decision Making Tools

LONDON, Dec. 1, 2020 /PRNewswire-PRWeb/ — TORA, the provider of industry leading trading technology, has today announced that it has...